Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydrocortisone vs Hydrocortisone + Fludrocortisone in Severe Sepsis
NCT00368381Phase 4Withdrawn
- Sponsor
- CAMC Health System
- Start
- Sep 2006
- Primary completion
- Jul 2009
- Modality
- Orthosteric Ligands
01
Overview
Phase 4, randomised, double-blind trial of fludrocortisone in sepsis and adrenal insufficiency (AI) (2 arms), sponsored by CAMC Health System. Primary endpoint: All cause mortality at 28 days. Planned start Sep 2006; status: withdrawn.
02
Drugs
fludrocortisone
03
Conditions
sepsisadrenal insufficiency (AI)
Beyond the preview
Go deeper on NCT00368381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00368381.